Clearmind Medicine Announces $2.7 Million Convertible Promissory Note Financing

On April 20, 2026, Clearmind Medicine Inc. announced that it entered into an agreement with existing investors to issue and sell convertible promissory notes in the aggregate principal amount of $2,700,000. This transaction is part of a previously announced securities purchase agreement from September 17, 2025, which allows for the issuance of up to $10,000,000 in convertible promissory notes. The current notes are being sold at an aggregate purchase price of $2,430,000, representing 90% of the principal amount. The company expects the transaction to close on or about April 21, 2026. The proceeds will provide the company with additional working capital to support its operations. This filing is incorporated by reference into the company's existing registration statements on Form F-3 and Form S-8. Clearmind Medicine is a biotech company focused on developing psychedelic-derived therapeutics to treat under-served health conditions, such as alcohol use disorder.